文章：

多参数流式细胞术在浆细胞疾病中的当前应用

Current applications of multiparameter flow cytometry in plasma cell disorders

原文发布日期：2017-10-20

DOI: 10.1038/bcj.2017.90

类型: Original Article

开放获取: 是

英文摘要：

Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenström macroglobulinemia.

摘要翻译： 

多参数流式细胞术（MFC）已成为浆细胞疾病患者管理中的标准技术，在常规临床实践的特定领域可视为必备手段。该技术因其能快速、明确地读取浆细胞克隆性，在鉴别诊断过程中发挥重要作用，同时为大多数单克隆丙种球蛋白病提供预后信息。随着多发性骨髓瘤治疗及疗效的近期进展，新的疗效评判标准已开始实施，其中将微小残留病（MRD）状态纳入最具相关性的临床终点指标之一，并有望作为生存期的替代指标。最新技术进步催生了新一代流式细胞术（NGF），该技术作为一种经认证、高灵敏度、成本效益优异且广泛可及的标准化MRD检测方法，也可用于循环肿瘤细胞的检测。本文综述了MFC与NGF在当前绝大多数浆细胞疾病（包括较少见的孤立性浆细胞瘤、轻链淀粉样变性或华氏巨球蛋白血症）中的应用。

原文链接：